title: Refocusing the war on cancer: the critical role of personalized treatment.
abstract: Despite very substantial investment and effort over the past 30 years, the overall survival rate of cancer patients has changed little. We propose that without a truly robust mechanism for selecting the right treatment for the right patient at the right time-the central concepts of personalized medicine-we will continue to see only incremental improvements and have little hope for substantial survival gains. We suggest that it is now imperative that future clinical trials be designed with a plan to incorporate biomarker development.
authors.affiliation: Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, USA.
authors.forename: Anil
authors.initials: A
authors.lastname: Potti
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Nevins
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D057285:Precision Medicine / Q000639:trends; D013048:Specimen Handling
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor